Uncontrolled cellular proliferation, mediated by dysregulation of the cell-cycle machinery
and activation of cyclin-dependent kinases (CDKs) to promote cell-cycle progression, lies at …

Dysregulation of the cell cycle is a hallmark of cancer that leads to aberrant cellular
proliferation. CDK4/6 are cyclin-dependent kinases activated in response to proliferative …

The cyclin D-cyclin dependent kinase (CDK) 4/6-inhibitor of CDK4 (INK4)-retinoblastoma
(Rb) pathway controls cell cycle progression by regulating the G1-S checkpoint …

Dysregulation of the cell cycle is a classic hallmark of cancer growth and metastatic
potential. Re-establishing cell cycle control through CDK inhibition has emerged as an …

Dysregulation of the cyclin dependent kinase pathway in luminal breast cancer creates a
new therapeutic opportunity for estrogen receptor positive breast cancer. Initial pan-CDK …

The ability to sustain unscheduled proliferation is a hallmark of cancer. The normal process
of cell division occurs via the cell cycle, a series of highly regulated steps that are …

CDK4/6 inhibitors have become game-changers in the treatment of estrogen receptor-
positive (ER+) breast cancer, and in combination with endocrine therapy are the standard of …

The cyclin-dependent kinase (CDK) 4/6 inhibitors belong to a new class of drugs that
interrupt proliferation of malignant cells by inhibiting progression through the cell cycle …

Deregulation of the cyclin D‐CDK4/6‐INK4‐RB pathway leading to uncontrolled cell
proliferation, is frequently observed in breast cancer. Currently, three selective CDK4/6 …

The recent arrival of CDK4/6 inhibitor agents, with an approximate doubling of progression-
free survival (PFS) associated with their use in hormone receptor-positive, HER2-negative …